UNCY (STOCKS)
Unicycive Therapeutics, Inc. Common Stock
$7.180000
-0.070000 (-0.97%)
Prev close: $7.250000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Shalabh Gupta
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $189.97M
- Employees
- 22
- P/E (TTM)
- -3.53
- P/B (TTM)
- 4.85
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
11
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.54 | $-0.49 | -0.0548 | -11.29% |
|
Dec 2025 (Q4)
|
$-0.82 | $-0.48 | -0.3362 | -69.64% |
|
Sep 2025 (Q3)
|
$-0.33 | $-0.57 | +0.2378 | +41.88% |
|
Jun 2025 (Q2)
|
$-0.52 | $-0.75 | +0.2348 | +31.11% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$9.98M |
| Operating Expenses | $29.97M |
| Research and Development | $8.57M |
| Other Operating Expenses | $21.40M |
| Operating Income/Loss | -$29.97M |
| Income/Loss From Continuing Operations After Tax | -$39.95M |
| Income/Loss From Continuing Operations Before Tax | -$39.95M |
| Net Income/Loss | -$39.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$39.95M |
| Net Income/Loss Available To Common Stockholders, Basic | -$39.95M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $1.00K |
| Preferred Stock Dividends And Other Adjustments | $1.00K |
| Basic Earnings Per Share | -$2.21 |
| Diluted Earnings Per Share | -$2.21 |
| Basic Average Shares | 56,123,781 |
| Diluted Average Shares | 56,123,781 |
| Assets | $64.41M |
| Current Assets | $63.55M |
| Noncurrent Assets | $861.00K |
| Fixed Assets | $48.00K |
| Other Non-current Assets | $813.00K |
| Liabilities | $26.70M |
| Current Liabilities | $26.49M |
| Accounts Payable | $1.14M |
| Other Current Liabilities | $25.35M |
| Noncurrent Liabilities | $217.00K |
| Equity | $37.70M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $37.70M |
| Liabilities And Equity | $64.41M |
| Net Cash Flow From Operating Activities | -$28.66M |
| Net Cash Flow From Operating Activities, Continuing | -$28.66M |
| Net Cash Flow From Investing Activities | -$17.23M |
| Net Cash Flow From Investing Activities, Continuing | -$17.23M |
| Net Cash Flow From Financing Activities | $63.49M |
| Net Cash Flow From Financing Activities, Continuing | $63.49M |
| Net Cash Flow | $17.60M |
| Net Cash Flow, Continuing | $17.60M |
| Comprehensive Income/Loss | -$39.95M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$39.95M |
| Other Comprehensive Income/Loss | -$39.38M |